Preclinical prediction of human brain target site concentrations: Considerations in extrapolating to the clinical setting

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3577-3593

  Westerhout, Joost ^a   Danhof, Meindert ^a   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Blood brain barrier (BBB); Blood cerebrospinal fluid barrier (BCSFB); Brain extracellular fluid (ECF); Central nervous system (CNS); Cerebrospinal fluid (CSF); Extrapolation; Mathematical model; Pharmacokinetics (PK); Physiological model; Transporters

Indexed keywords

MORPHINE; SALICYLIC ACID; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN HOMOGENATE; BRAIN PERFUSION; BRAIN SLICE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; MATHEMATICAL MODEL; NONHUMAN; PLASMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 79960159776     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22604     Document Type: Review

References (159)

1. World Health Organization Report on "Neurological Disorders: Public Health Challenges, "2007.
2. Business Insights LTD, Londen, UK, 2010. "The CNS Market Outlook to 2014".
3. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. 2008. On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
4. de Lange ECM, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Del Rev 45:125-148.
5. Hammarlund-Udenaes M. 2009. Active-site concentrations of chemicals-Are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215-220.
6. de Lange ECM, Danhof M. 2002. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703.
7. Shen DD, Artru AA, Adkison KK. 2004. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857.
8. Lin JH. 2008. CSF as a surrogate for assessing CNS exposure: An industrial perspective. Curr Drug Metab 9:46-59.
9. Peletier LA, Benson N, van Der Graaf PH. 2009. Impact of plasma-protein binding on receptor occupancy: An analytical description. J Theor Biol 265:253-262.
10. Mayer S, Maickel RP, Brodie BB. 1959. Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. J Pharmacol Exp Ther 127:205-211.
11. Pardridge WM. 1995. Transport of small molecules through the blood-brain barrier: Biology and methodology. Adv Drug Del Rev 15:5-36.
12. Morgan DJ, Huang JL. 1993. Effect of plasma protein binding on kinetics of capillary uptake and efflux. Pharm Res 10:300-304.
13. Tanaka H, Mizojiri K. 1999. Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther 288:912-918.
14. Mandula H, Parepally JMR, Feng R, Smith QR. 2006. Role of site-specific binding to plasma albumin in drug availability to brain. J Pharmacol Exp Ther 317:667-675.
15. Davson H, Oldendorf WH. 1967. Transport in the central nervous system. Proc R Soc Med 60:326-329.
16. Abbott NJ, Rönnbäck L, Hansson E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53.
17. Bernacki J, Dobrowolska A, Nierwińska K, Malecki A. 2008. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 60:600-622.
18. Abbott NJ. 2004. Evidence of bulk flow of brain interstitial fluid: Significance for physiology and pathology. Neurochem Int 45:545-552.
19. Wolburg H, Paulus W. 2010. Choroid plexus: Biology and pathology. Acta Neuropathol 119:75-88.
20. Pardridge WM. 2002. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139.
21. Dohrmann GJ. 1970. The choroid plexus: A historical review. Brain Res 18:197-218.
22. Lee G, Dallas S, Hong M, Bendayan R. 2001. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596.
23. Lee G, Bendayan R. 2004. Functional expression and localization of P-glycoprotein in the central nervous system: Relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 21:1313-1330.
24. Roberts LM, Black DS, Raman C, Woodford K, Zhou M, Haggerty JE, Yan AT, Cwirla SE, Grindstaff KK. 2008. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neurosci 155:423-438.
25. Keep RF, Jones HC. 1990. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Dev Brain Res 56:47-53.
26. Gjedde A. 1981. High- and low-affinity transport of d-glucose from blood to brain. J Neurochem 36:1463-1471.
27. Keep RF, Jones HC. 1990. Cortical microvessels during brain development: A morphometric study in the rat. Microvasc Res 40:412-426.
28. Graff CL, Pollack G. 2004. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 5:95-108.
29. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, Van Der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
30. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, Van Der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. 1997. Normal viability and altered pharmacogenetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad U S A 94:4028-4033.
31. Schinkel AH. 1999. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Del Rev 36:179-194.
32. Wijnholds J, de Lange ECM, Scheffer GL, Van Den Berg D-J, Mol CAAM, Van Der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. 2000. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105:279-285.
33. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. 1999. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96:3900-3905.
34. 4) transfer from CSF to choroid plexus and ventricular brain regions in rabbit: Contributory role of P-glycoprotein and organic anion transporting polypeptides. Brain Res 1181:44-50.
35. Ghersi-Egea JF, Perrin R, Leininger-Muller B, Grassiot MC, Jeandel C, Floquet J, Cuny G, Siest G, Minn A. 1993. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol 45:647-658.
36. Ghersi-Egea JF, Leininger-Muller B, Suleman G, Siest G, Minn A. 1994. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J Neurochem 62:1089-1096.
37. Cserr HF. 1965. Potassium exchange between cerebrospinal fluid, plasma, and brain. Am J Physiol 209:1219-1226.
38. Kimelberg HK. 2004. Water homeostasis in the brain: Basic concepts. Neurosci 129:851-860.
39. Miyan JA, Nabiyouni M, Zendah M. 2003. Development of the brain: A vital role for cerebrospinal fluid. Can J Physiol Pharmacol 81:317-328.
40. Segal MB. 1993. Extracellular and cerebrospinal fluids. J Inher Metab Dis 16:617-638.
41. 14C]inulin in rat. Neurosci 95:577-592.
42. Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. 1992. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol 262:R20-R24.
43. Kohn MI, Tanna NK, Herman GT, Resnick SM, Mozley PD, Gur RE, Alavi A, Zimmerman RA, Gur RC. 1991. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 178:115-122.
44. 14C]inulin after intrathecal infusion. Brain Res 52:323-332.
45. Cserr HF, Cooper DN, Suri PK, Patlak CS. 1981. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol 240:F319-F328.
46. Begley DJ. Transport to the brain. In: Begley DJ, Bradbury MW, Kreuter J, editors. The blood-brain barrier and drug delivery to the CNS. New York: Dekker 2000: 93-108.
47. Scism JL, Powers KM, Artru AA, Lewis L, Shen DD. 2000. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: A microdialysis study. Brain Res 884:77-86.
48. de Lange ECM, Danhof M, de Boer AG, Breimer DD. 1997. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Rev 25:27-49.
49. Hammarlund-Udenaes M, Bredberg U, Fridén M. 2009. Methodologies to assess brain drug delivery in lead optimization. Curr Topics Med Chem 9:148-161.
50. Levin VA. 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684.
51. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. 2000. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
52. Crone C. 1965. The permeability of brain capillaries to non-electrolytes. Acta Physiol Scand 64:407-417.
53. Oldendorf WH. 1970. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 24:372-376.
54. Ohno K, Pettigrew KD, Rapoport SI. 1978. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235:H299-H307.
55. Takasato Y, Rapoport S, Smith QR. 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
56. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. 2009. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
57. 14C-mannitol using the rat in situ brain perfusion technique. Dev Brain Res 87:69-76.
58. Deane R, Zheng W, Zlokovic BV. 2004. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferring-bound and free iron into the rat brain. J Neurochem 88:813-820.
59. Liu X, Jia L. 2007. The conduct of drug metabolism studies considered good practice (I): Analytical systems and in vivo studies. Curr Drug Metab 8:815-821.
60. Lin JH, Sugiyama Y, Awazu S, Hanano M. 1982. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm 10:637-647.
61. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. 2009. Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753-760.
62. Kalvass JC, Maurer TS. 2002. Influence of nonspecific brain and plasma binding of CNS exposure: Implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
63. +. J Cereb Blood Flow Metab 11:398-406.
64. Kakee A, Terasaki T, Sugiyama Y. 1996. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559.
65. Fridén M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. 2009. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37:1226-1233.
66. Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. 2007. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Disp 35:1711-1719.
67. Read KD, Braggio S. 2010. Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6:337-344.
68. Danhof M, Levy G. 1984. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther 229:44-50.
69. Hill KK, West SA, Ekhator NN, Bruce AB, Wortman MD, Baker DG, Geracioti Jr TD. 1999. The effect of lumbar puncture stress on dopamine and serotonin metabolites in human cerebrospinal fluid. Neurosci Lett 276:25-28.
70. Bruce JN, Oldfield EH. 1988. Method for sequential sampling of cerebrospinal fluid in humans. Neurosurgery 23:788-790.
71. Cserr HF. 1971. Physiology of the choroid plexus. Physiol Rev 51:273-311.
72. Bouman HJ, van Wimersma Greidanus TB. 1979. A rapid and simple cannulation technique for repeated sampling of cerebrospinal fluid in freely moving rats. Brain Res Bull 4:575-577.
73. 2α. Pharmacol Biochem Behav 13:235-242.
74. van Bree JBMM, Baljet AV, van Geyt A, de Boer AG, Danhof M, Breimer DD. 1989. The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system. J Pharmacokinet Biopharm 17:441-462.
75. De La Calle JL, Paíno CL. 2002. A procedure for direct lumbar puncture in rats. Brain Res Bull 59:245-250.
76. Wang X, Kimura S, Yazawa T, Endo N. 2005. Cerebrospinal fluid sampling by lumbar puncture in rats-Repeated measurements of nitric oxide metabolites. J Neurosci Meth 145:89-95.
77. Summerfield SG, Jeffrey P. 2006. In vitro prediction of brain penetration-A case for free thinking? Expert Opin Drug Discov 1:595-607.
78. Lorenzo AV, Spector S. 1973. Transport of salicylic acid by the choroid plexus in vitro. J Pharmacol Exp Ther 184:465-471.
79. Maurer TS, DeBartolo DB, Tess DA, Scott D. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
80. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J. 2006. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447.
81. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. 2009. Structure-Brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
82. Sabol KE, Freed CR. 1988. Brain acetaminophen measurement by in vivo dialysis, in vivo electrochemistry and tissue assay: A study of the dialysis technique in the rat. J Neurosci Meth 24:163-168.
83. Nicolaysen LC, Pan HT, Justice Jr JB. 1988. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res 456:317-323.
84. Morrison PF, Bungay PM, Hsiao JK, Ball BA, Mefford IN, Dedrick RL. 1991. Quantitative microdialysis: Analysis of transients and application to pharmacokinetics in brain. J Neurochem 57:103-119.
85. Ståhle L, Segersvärd S, Ungerstedt U. 1991. Drug distribution studies with microdialysis II. Caffeine and theophylline in blood, brain and other tissues in rats. Life Sci 49:1843-1852.
86. Terasaki T, Deguchi Y, Sato H, Hirai K, Tsuji A. 1991. In vivo transport of a dynorphin-like analgesic peptide, E-2078, through the blood-brain barrier: An application of brain microdialysis. Pharm Res 8:815-820.
87. Wong SL, Wang Y, Sawchuk RJ. 1992. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm Res 9:332-338.
88. de Lange ECM, Danhof M, de Boer AG, Breimer DD. 1994. Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res 666:1-8.
89. Wang Q, Yang H, Miller DW, Elmquist WF. 1995. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem Biophys Res Comm 211:719-726.
90. Sun L, Stenken JA. 2003. Improving microdialysis extraction efficiency of lipophilic eicosanoids. J Pharm Biomed Anal 33:1059-1071.
91. Matos FF, Rollema H, Basbaum AI. 1992. Simultaneous measurement of extracellular morphine and serotonin in brain tissue and CSF by microdialysis in awake rats. J Neurochem 58:1773-1781.
92. Malhotra BK, Lemaire M, Sawchuk, RJ. 1994. Investigation of the distribution of EAB 515 to cortical ECF and CSF in freely moving rats utilizing microdialysis. Pharm Res 11:1223-1232.
93. van Waarde A. 2000. Measuring receptor occupancy with PET. Curr Pharm Des 6:1593-1610.
94. 2 receptor occupancy in risperidone-treated schizophrenic patients. J Nucl Med 39:1138-1142.
95. 123I]ADAM: A SPECT validation study. Eur J Nucl Med Mol Im 32:1329-1336.
96. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psych 161:818-825.
97. 2 receptor occupancy for long-acting injectable risperidone. Am J Psych 163:396-401.
98. Kouris K. 1984. Emission tomography: A concise theoretical overview. Nucl Med Comm 5:733-739.
99. Haubner R. 2010. PET radiopharmaceuticals in radiation treatment planning-Synthesis and biological characteristics. Radiother Oncol 96:280-287.
100. Claassen V. Techniques in the Behavioral and Neural Sciences, Neglected Factors in Pharmacology and Neuroscience Research, Vol. 12, 1994, Ed JB Hoston, Elsevier, the Netherlands.
101. Neuwelt EA, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenburg GA, Smith Q, Drewes LR. 2008. Strategies to advance translational research into brain barriers. Lancet Neurol 7:84-96.
102. Cserr HF, Bundgaard M. 1984. Blood-brain interfaces in vertebrates: A comparative approach. Am J Physiol 246:R277-R288.
103. Jeffrey P, Summerfield S. 2010. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis 37:33-37.
104. Syvänen S, Lindhe Ö, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, Hammarlund-Udenaes M. 2009. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
105. Miller DS. 2010. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31:246-254.
106. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW. 1998. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 44:592-600.
107. Neuwelt EA. 2004. Mechanisms of disease: The blood-brain barrier. Neurosurg 54:131-142.
108. Roberts DJ, Goralski KB. 2008. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 4:1245-1264.
109. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW. 2002. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brain of elderly non-demented humans. Pharmacogenetics 12:535-541.
110. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J. 2004. The role of P-glycoprotein in cerebral amyloid angiopathy: Implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1:121-125.
111. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic B, Piwnica-Worms D, Holtzman DM. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285-3290.
112. Vogelgesang S, Glatzel M, Walker LC, Kroemer HK, Aguzzi A, Warzok RW. 2006. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeld-Jakob disease. Acta Neuropathol 111:436-443.
113. Vautier S, Fernandez C. 2009. ABCB1: The role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol 5:1349-1358.
114. Langford D, Grigorian A, Hurford R, Adame A, Ellis RJ, Hansen L, Masliah E. 2004. Altered P-gp expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 63:1038-1047.
115. 11C]verapamil and PET. Eur J Clin Pharmacol 65:941-946.
116. Löscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Nat Rev Neurosci 6:591-602.
117. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738.
118. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
119. Hoffmayer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478.
120. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. 2003. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448.
121. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Béliveau R. 2002. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 38:339-348.
122. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: Polygenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Eur J Physiol 447:653-665.
123. Vannucci SJ. 1994. Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. J Neurochem 62:240-246.
124. Choudhuri S, Cherrington NJ, Li N, Klaassen CD. 2003. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos 31:1337-1345.
125. Begley DJ. 2004. ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1295-1312.
126. Kusuhara H, Sugiyama Y. 2004. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Del Rev 56:1741-1763.
127. Kusuhara H, Sugiyama Y. 2005. Active efflux across the blood-brain barrier: Role of the solute carrier family. NeuroRx 2:73-85.
128. Löscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76.
129. Perrière N, Yousif S, Cazaubon S, Chaverot N, Bourasset F, Cisternino S, Declèves X, Hori S, Terasaki T, Deli M, Scherrmann J-M, Temsamani J, Roux F, Couraud P-O. 2007. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res 1150:1-13.
130. Maurer MH. 2010. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev 29:17-28.
131. Ito H, Inoue K, Goto R, Kinomura S, Taki Y, Okada K, Sato K, Sato T, Kanno I, Fukuda H. 2006. Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry. Ann Nucl Med 20:131-138.
132. Harashima H, Sawada Y, Sugiyama Y, Iga T, Hanano M. 1985. Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J Pharmacokinet Biopharm 13:425-550.
133. Danhof M, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191.
134. Fleishaker JC, Smith RB. 1987. Compartmental model analysis in pharmacokinetics. J Clin Pharmacol 27:922-926.
135. Bonati M, Latini R, Tognini G, Young JF, Garattini S. 1984. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metab Rev 15:1355-1383.
136. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
137. Lavé T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA, Schmitt M. 1999. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 49:178-183.
138. Mahmood I, Balian JD. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokin 36:1-11.
139. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. 2007. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet 46:433-447.
140. 1A receptor mediated responses from rat to man. Pharm Res 24:2031-2039.
141. Dedrick RL. 1973. Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
142. Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
143. Mordenti J. 1986. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040.
144. Colburn WA. 1988. Physiologic pharmacokinetic modeling. J Clin Pharmacol 28:673-677.
145. Ings RMJ. 1990. Interspecies scaling and comparisons in drug development and toxicogenetics. Xenobiotica 20:1201-1231.
146. Espié P, Tytgat D, Sargentini-Maier M-L, Poggesi I, Watelet J-P. 2009. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391-407.
147. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report (Georgetown university, Washington, DC, May 29-30, 2002). AAPS PharmSci. 6:E6.
148. Jones HM, Gardner IB, Watson KJ. 2009. Modelling and PBPK simulation in drug discovery. AAPS J 11:155-166.
149. Jones HM, Parrott N, Jorga K, Lavé T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokin 45:511-542.
150. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. 1997. Kinetic evidence for active transport across the blood-brain barrier of quinolone antibiotics. J Pharmacol Exp Ther 283:293-304.
151. Breimer DD, Danhof M. 1997. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm. Clin Pharmacokinet 32:259-267.
152. Swinghammer TL, Kroboth PD. 1988. Basic concepts in pharmacodynamic modeling. J Clin Pharmacokinet 28:388-394.
153. Csajka C, Verotta D. 2006. Pharmacokinetic-pharmacodynamic modeling: History and perspectives. J Pharmacokinet Pharmacodyn 33:227-279.
154. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
155. Colburn WA. 1981. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokin Biopharm 9:367-388.
156. Colburn WA. 1988. Combined pharmacokinetic/pharmacodynamic (PK/PD) modeling. J Clin Pharmacol 28:769-771.
157. Mager DE, Woo S, Jusko WJ. 2009. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokin 24:16-24.
158. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. 2005. Mechanism-based pharmacokinetic-pharmacodynamic modelling-A new classification of biomarkers. Pharm Res 22:1432-1437.
159. Danhof M, de Jongh J, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400.